Section 11

# Michigan Community Integrated Paramedicine Protocols Table of Contents

Initial Date: December 21, 2020

Revised Date: 10/28/22

#### **Program Protocols**

- 11-01 CIP Program Policy
- 11-02 CIP Medical Director Roles and Responsibilities
- 11-03 CIP Medical Direction
- 11-04 CIP Scope of Service/Treatment Capabilities
- 11-05 CIP Documentation
- 11-06 CIP Program Enrollment
- 11-07 CIP Patient Service Plan/Care Plan
- 11-08 CIP Program Discharge

#### **Procedure Protocols**

- 11-26 CIP Fall Risk Reduction Assessment
- 11-27 CIP SDOH Assessment
- 11-28 CIP Medication Audit
- 11-29 CIP Feeding Tube
- 11-30 CIP Urinary Catheter
- 11-31 CIP Ostomies
- 11-32 CIP Nasal Packing
- 11-33 CIP Specimen Collection
- 11-34 CIP Point of Care Testing for Blood Analysis
- 11-35 CIP Suture Removal
- 11-36 CIP Otoscope
- 11-37 CIP PICC Access
- 11-38 CIP Vaccinations
- 11-39 CIP Naloxone Leave Behind
- 11-40 CIP HOLD for MAT protocol
- 11-41 CIP Naloxone Medication Kit Contents and Distribution

#### Treatment Protocols: Chronic Condition Care

- 11-50 CIP Patient General Assessment and Care
- 11-51 CIP Diabetic Care
- 11-52 CIP Asthma Care
- 11-53 CIP Chronic Obstructive Pulmonary Disease Care
- 11-54 CIP Congestive Heart Failure Care
- 11-55 CIP Chronic Hypertension Care
- 11-56 CIP Post MI or Cardiac Intervention Care
- 11-57 CIP Post Orthopedic Surgery Care
- 11-58 CIP Post Stroke Care
- 11-59 CIP Prenatal Care

# Michigan Community Integrated Paramedicine Protocols Table of Contents

Initial Date: December 21, 2020 Section 11

Revised Date: 10/28/22

- 11-60 CIP Mother/Infant Postpartum Care
- 11-61 CIP Sleep Apnea Care
- 11-62 CIP Wound Care
- 11-63 CIP Substance Use Disorder Care

#### **Treatment Protocols: Complaints**

- 11-75 CIP Skin Rash Complaints
- 11-76 CIP Urinary Complaints
- 11-77 CIP Gastrointestinal Complaints
- 11-78 CIP Suspected Respiratory Infection Complaints
- 11-79 CIP Sore Throat Complaints
- 11-80 CIP Nontraumatic Nosebleed Complaints
- 11-81 CIP Sexual Assault Follow Up



PROGRAM POLICY

Initial Date: July 23, 2020

Revised Date: Section 11-01

**Purpose:** To establish minimum and consistent requirements for MDHHS approved CIP Special Study programs throughout Michigan.

#### I. Definitions and Acronyms

- a. CIP Community Integrated Paramedicine: The MDHHS umbrella term. encompassing both Community Paramedicine and Mobile Integrated Health
  - i. CP Community Paramedicine: Providers possess broad based MDHHS approved education. CP programs may conduct both scheduled and unscheduled visits as approved by the MCA and may take referrals directly from the 9-1-1 system.
  - ii. MIH Mobile Integrated Health: Providers possess focused MDHHS approved education enabling them to conduct care outlined in a single MDHHS approved CIP protocol. MIH programs conduct scheduled visits.
- b. CP Community Paramedic: A paramedic who has successfully completed an MDHHS approved community paramedicine education program.
- c. MIH Paramedic Mobile Integrated Health Paramedic: A paramedic who has fulfilled the education requirement set forth by the MCA to conduct care as outlined in a MDHHS approved CIP protocol.
- d. CPU CP Unit: A vehicle licensed as and compliant with MDHHS standards as an ALS transporting vehicles, or an ALS non-transporting vehicle. A CP Unit must be utilized to conduct any, and all CIP care with the single exception of a community outreach provider visit see Community Outreach Provider Visit protocol.
- e. CIP MD Community Integrated Paramedicine Medical Director Physician with oversight for CIP program (s). This may be the MCA Medical Director or an MCA and MDHHS approved designee.
- f. QATF Quality Assurance Task Force
- g. SDOH Social Determinants of Health "conditions in the places where people live, learn, work, and play that affect a wide range of health and qualityof life-risks and outcomes" (CDC).
- II. CIP Program Requirements
  - a. All CIP programs must:
    - i. Be approved by MDHHS as a Special Study.
    - ii. Be approved by the MCA.
    - iii. Possess a CIP Medical Director approved by the MCA and MDHHS.
    - iv. Utilize only personnel that have met MDHHS education requirements
    - v. Conduct care within the parameters of the MCA's adopted MDHHS approved protocols
    - vi. Comply with MDHHS guidelines.
    - vii. Further and without contradiction to MDHHS guidelines, comply with MCA guidelines.
    - viii. Further and without contradiction to MDHHS or MCA guidelines, comply with agency guidelines.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



PROGRAM POLICY

Initial Date: July 23, 2020

Revised Date: Section 11-01

- b. CIP Special Study programs are allotted an initial 3-year term to provide services.
  - CIP Special Study programs may be terminated at any time by the privileging MCA or MDHHS for failure to comply with MDHHS or MCA requirements.
  - ii. CIP Special Study programs will be reviewed by the QATF 3 years after the initial approval date. Programs will be:
    - Continued as special studies with continued MDHHS oversight and reviews
    - 2. Discontinued
- III. CIP Protocol Requirements
  - a. All CIP programs will adopt the following MDHHS approved protocols, or an MCA adapted version approved by MDHHS which achieves the same goals:
    - i. CIP Program Policy.
    - ii. CIP Medical Director Role & Responsibility.
    - iii. CIP Medical Direction.
    - iv. CIP Scope of Service/Treatment Capability.
    - v. CIP Documentation.
    - vi. CIP Program Enrollment
    - vii. CIP Patient Service Plan/Care Plan
    - viii. CIP Program Discharge
    - ix. CIP Fall Risk Reduction Assessment
    - x. CIP SDOH Assessment
    - xi. CIP Medication Audit
    - xii. CIP Patient General Assessment and Care
  - b. All CIP programs will have MDHHS approved protocols that address the following:
    - i. CIP procedures performed.
    - ii. CIP medications administered.
    - iii. CIP treatments and focused populations served.
  - c. All CIP programs will have protocols or MCA and MDHHS approved policies and procedures that address:
    - i. Personnel requirements.
    - ii. Minimum staffing requirements.
    - iii. Dispatching requirements.
    - iv. Personal vehicle usage.
    - v. Vulnerable adult recognition.
    - vi. Reporting process for suspected adult or child neglect, abuse, or exploitation.
    - vii. Patient encounters outside of work.
    - viii. Self-reporting for suspected errors.
    - ix. Receipt of gifts.
    - x. Conflict of interest language that prohibits providers from entering relationships or signing documentation that results in a recognized

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



PROGRAM POLICY

Initial Date: July 23, 2020 Revised Date:

Section 11-01

position of authority or advocacy on the patient's behalf regardless of legal recognition

- d. Protocols must be reviewed minimally every 3 years
- e. In the event an MCA has adopted procedure or treatment protocols which do not apply to all CIP programs within the MCA, it will be up to the MCA develop a Quality Assurance system to ensure programs are only utilizing medications and the corresponding protocols for which they are credentialed.

#### IV. Reporting Requirements

- a. CIP Data Submission
  - i. All CIP programs will submit MDHHS required data directly to MDHHS on the quarterly basis that a minimum will include:
    - 1. Number of visits conducted (both unique patients and total number of visits)
    - 2. Number of patients that accepted enrollment into the CIP program (if applicable)
    - 3. Average number of patients enrolled at any given time during the quarter (if applicable)
    - Number of patients that received at least one CIP Fall Risk Reduction Assessment
    - Number of patients receiving at least one CIP Fall Risk Reduction Assessment in which a correction or referral needed to be made
    - Number of patients that received at least one CIP Medication Audit
    - 7. Number of patients that received at least one CIP Medication Audit in which a correction or referral needed to be made
    - 8. Number of patients that received at least one CIP SDOH Assessment
    - Number of patients that received at least one CIP SDOH
       Assessment in which a correction or referral needed to be made
    - 10. Number of CIP calls that ended in a disposition of patient being transported to or sent to the emergency room by any mode of transportation.
    - 11. Additional MDHHS reporting requirements will be based on the CIP programs specific lines of service.
  - ii. All CIP programs will submit MCA required data to the MCA per the schedule established by the MCA.
  - iii. MCA's will submit all collected data to MDHHS on the quarterly basis.
- b. The following events must be reported to the CIP-MD and the MCA within 24 hours of the occurrence regardless of conclusion of an investigation.
  - i. Death of a patient suspected to be related to the actions or inactions of a CIP provider or program.
  - ii. Illness or injury suspected to be related to the action or inactions of a CIP provider or program.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Protocol Source/References: CDC - https://wwwifede.ipt//sealthdeentiting.nls/formation

Approval Date: 11/12/2024 Page **3** of **4** 



# Michigan COMMUNITY INTEGRATED PARAMEDICINE Program Protocol PROGRAM POLICY

Initial Date: July 23, 2020

Revised Date: Section 11-01

iii. Accusations of misconduct, practicing outside of the established protocol dictated scope of CIP practice or abuse of power.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Protocol Source/References: CDC - https://wwwifereight/usetthderesiting-res



CIP MEDICAL DIRECTOR ROLE AND RESPONSIBILITIES

Initial Date: July 23, 2020

Revised Date: Section 11-02

**Purpose:** To outline the roles and responsibilities of the CIP Medical Director.

- I. A CIP Medical Director will be the MCA Medical Director and additionally may be
  - a. A physician appointed by the MCA Medical Director and approved by both the Medical Control Board and MDHHS (optional)
- II. CIP Medical Director responsibilities:
  - a. Medical operations of specified CIP program(s)
  - b. Development of CIP protocols
  - c. CIP personnel criteria and selection process
  - d. Credentialing (MCA privileges) of CIP personnel
  - e. Establishing a quality assurance process and schedule which must be approved by the following:
    - i. MCA
    - ii. MDHHS
  - f. Remediation of CIP personnel, as necessary.
    - MDHHS and the MCA Medical Director must be advised of any CIP requiring remediation within 30 days of the incident
  - g. Development and oversight of CIP continuing education
  - h. Data submission to the MCA
  - i. Data submission to MDHHS
- III. The CIP MD privileges are at the discretion of the MCA Medical Director and the MCA Board. CIP Programs are not allowed to function in an MCA without expressed approval from the MCA and MDHHS.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Protocol Source/References: CDC - https://www.cdc.gov/socialdeterminants/



# Michigan COMMUNITY INTEGRATED PARAMEDICINE Program Protocol MEDICAL DIRECTION

Initial Date: July 23, 2020

Revised Date: Section 11-03

#### **Medical Direction**

- I. CIP providers will be continuously monitoring for signs of life-threatening or urgent but not life-threatening medical needs. If a CIP provider encounters:
  - a. Life threatening medical needs
    - i. Initiate local 9-1-1 response
  - b. <u>Urgent but not life-threatening</u> medical needs beyond what is written in the orders for the visit.
    - May initiate local 9-1-1 response prior to establishing online medical direction
    - ii. Hierarchy for establishing online medical direction.
      - a. First contact MCA approved referring physician
      - b. If unsuccessful, second contact will be the MCA approved referring physician's on-call service provider
      - c. If unsuccessful, third contact will be the CIP Medical Director (if applicable)
      - d. If unsuccessful, fourth contact will be the MCA's online medical control
      - e. If unsuccessful, initiate local 9-1-1 response

II. Non-Urgent Medical Needs

- a. Medical Direction for CIP visits that lack immediate life-threatening or urgent medical needs may be provided by:
  - i. Online MCA Medical Direction
  - ii. MCA approved referring physician
  - iii. MCA approved Primary Care Physician (PCP)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



SCOPE OF SERVICE/TREATMENT CAPABILITIES

Initial Date: July 23, 2020

Revised Date: Section 11-04

**Purpose:** To communicate the program types, patient protocols, and procedures allowed within the MCA. Marked categories will have corresponding protocols. MCA's will track and report to MDHHS the protocols applicable to each CIP Program.


1.	CIP F II.	Program Types will include (choose from the following): Scheduled appointment and physician's order using Community Outreach Provider Visit protocol (no minimum vehicle requirement)
		a. Community Paramedic (optional)
	III.	<ul> <li>b.</li></ul>
	IV.	<ul> <li>b.</li></ul>
	V.	b. Mobile Integrated health Paramedic (optional)  Low acuity 9-1-1 calls  a. Community Paramedia
2.		a. Community Paramedic     it protocols     Will include:         i. CIP Patient General Assessment and Care
	b.	May include:
		i. CIP Diabetic Care
		ii. CIP Asthma Care
		iii. CIP Chronic Obstructive Pulmonary Disease Care
		iv. CIP Congestive Heart Failure
		v. CIP Chronic Hypertension Care
		vi. CIP Post MI or Cardiac Intervention Care
		vii. CIP Post Orthopedic Surgery Care
		viii. CIP Post Stroke Care
		ix. CIP Prenatal Care
		x. CIP Mom/Baby Postpartum Care



SCOPE OF SERVICE/TREATMENT CAPABILITIES

Initial Date: July 23, 2020

Revised Date: Section 11-04





SCOPE OF SERVICE/TREATMENT CAPABILITIES

Initial Date: July 23, 2020

Revised Date: Section 11-04

xii



CIP Naloxone Leave Behind

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



# Michigan COMMUNITY INTEGRATED PARAMEDICINE Program Protocol DOCUMENTATION

Initial Date: July 23, 2020

Revised Date: Section 11-05

#### **Purpose:** To provide guidance for documentation of CIP services

- I. Patient contacts will be documented in an EPCR system including:
  - a. Face to face contact with or without treatments rendered
  - b. Telephone/telehealth contact
- II. Communications with all persons regarding a patient will be documented in an EPCR system. Examples include but are not limited to:
  - a. Licensed health care providers
    - i. Communications with licensed health care providers that influence the route of care (receiving an order from or reporting an issue to) should include name, agency, date, time and issue relayed to provider.
  - b. Family members
  - c. Social service organizations
  - d. Meals on wheels
  - e. Volunteer organizations
  - f. Community organizations
- III. EPCRs will be available to the referring physician within 24 hours of the completion of the visit. Transmission of electronic records will be determined by MCA.
- IV. Things that cannot be documented directly into the EPCR will be attached to the EPCR. This includes but is not limited to forms and checklist that are not housed within the EPCR such as:
  - a. Consent forms
  - b. Physician created care plans
  - c. Checklists
  - d. Medication lists
  - e. Physician's orders
- V. Procedure protocol documentation will include:
  - a. Evaluation findings
  - b. Interventions
  - Response to interventions (Results may be improved, unchanged, or worsened)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### CIP PROGRAM ENROLLMENT

Initial Date: July 23, 2020

Revised Date: Section 11-06

**Purpose:** To provide guidelines for patient enrollment into Community Integrated Paramedicine Programs.

- I. Enrollment to a CIP program will be necessary in the following situations:
  - a. A physician's referral
  - b. Anticipation of more than 1 visit (includes but not limited to phone, telehealth/telemedicine, in person).
- II. Enrollment will include:
  - a. Physician's referral (physician name should be documented in EPCR)
  - b. Documented patient consent
  - c. Documented intake assessment including but not limited to:
    - i. Physical assessment with notation to overall physical and mental statuses and limitations both physical and cognitive
    - ii. Fall risk reduction assessment see Fall Risk Reduction Assessment protocol
    - iii. Social determinants of health assessment see SDOH Assessment protocol
    - iv. Medication audit see Medication Audit protocol (optional)
  - d. Development of a service plan/care plan
- III. Patient enrollment including the intake assessment must be documented within the EPCR or attached to the EPCR
- IV. Whenever possible CIP services should work in conjunction with already established services available within the community.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### CIP PATIENT SERVICE PLAN/CARE PLAN

Initial Date: July 23, 2020

Revised Date: Section 11-07

**Purpose:** To outline the minimum elements that must be included in a service plan/care plan for patient's enrolled in CIP programs.

- I. The CIP patient service plan/care plan will include (if applicable):
  - a. Short and long-term health care needs and goals including timeframes for meeting the goals (including end of life care).
  - b. A description of the out-of-hospital services needed to address and satisfy the patient's needs and goals.
  - c. Frequency of visits and projected number of visits.
  - d. A goal for the patient's discharge
  - e. Medications administered
  - f. Medication audits performed and findings
  - g. Prescriptions provided
  - h. Decline in physical or mental health
  - i. Decline in mobility or capacity for self-care
  - j. Change in environment or person's residing within the environment
  - k. Admission to a hospital
  - I. Medications or treatment rendered
  - m. Unscheduled or episodic care provided by the CIP program
  - n. Clinic or physician follow up schedule and logistics for follow up compliance if indicated.
- II. The CIP patient service plan/care plan will be updated upon each visit.
- III. The CIP service plans/care plan must be documented within the EPCR or attached to the EPCR.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



CIP PROGRAM DISCHARGE

Initial Date: July 23, 2020

Revised Date: Section 11-08

**Purpose:** To provide guidelines for patient discharge or disenrollment from a Community Integrated Paramedicine Program.

Aliases: Dis-enrollment, graduation

- I. Planned Discharges
  - a. Goals met and physician discharges
  - b. Expirations of physician's order
  - c. Referral to higher level of care
- II. Unplanned Discharges
  - a. Cancelation/missing more than 3 visits without notice or valid cause
  - b. Non-adherence to goals
  - c. Relocation
  - d. Patient/family request
  - e. Unsafe situation for the CIP provider
  - f. Death
- III. Discharge documentation will include:
  - a. How and when the patient was informed
  - b. How and when the ordering physician was informed
  - c. Health status upon last visit
  - d. Concerns of discontinued care
  - e. Persons informed of concerns
- IV. Discharges must be documented within the EPCR or attached to the EPCR.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### FALL RISK REDUCTION ASSESSMENT

Initial Date: August 28, 2020

Revised Date: Section 11-26

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for the minimum elements of a fall risk reduction assessment and when it should be performed with the intent of reducing preventable falls.

Aliases: Home safety assessment, Fall risk check

- I. Indications
  - a. CIP encounter
- II. Contraindication
  - a. None
- III. Equipment
  - a. MCA approved fall risk reduction assessment checklist which will include
    - i. Evaluation of environment
    - ii. Evaluation of patient's ability in current state to maneuver in environment
  - b. An MCA may elect to use an MCA approved abbreviated version of the fall risk reduction checklist for the following situations:
    - i. Subsequent visits of an enrolled patient with no notable change in environment or patient status.
    - ii. Non-scheduled visits that do not allow time for a fall risk reduction assessment due to the disposition of the patient
- IV. Procedure
  - a. Perform fall risk reduction assessment following MCA approved checklist.
  - b. Findings that present threats to the patient's immediate health and well-being must be reported to the referring prior to the conclusion of the visit.
- V. Documentation see CIP Documentation protocol
  - a. Additionally
    - i. Completion of checklist
    - ii. Findings
    - iii. Corrections or plan for corrections
    - iv. Inability to complete corrections and reason

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



SOCIAL DETERMINANTS OF HEALTH ASSESSMENT

Initial Date: August 28, 2020

Revised Date: Section 11-27

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for the minimum elements of a Social Determinants of Health (SDOH) assessment and when it should be performed with the intent of reducing barriers to optimal health.

#### Aliases: Health care barriers

- I. Indications
  - a. Intake/enrollment assessments
  - b. Referring physician request
  - c. As deemed necessary by CIP provider
- II. Contraindications
  - a. None
- III. Equipment
  - a. MCA approved SDOH Assessment Form which will include:
    - Housing, transportation access, safety within their environment, food security, social exclusion, social support, healthcare access and addiction.
- IV. Procedure
  - a. Perform SDOH assessment following MCA approved checklist.
  - b. Assess both the patient and their environment
  - c. Findings that present threats to the patient's immediate health and well-being must be reported to the referring physician prior to conclusion of the visit.
- V. Documentation see CIP Documentation protocol
  - a. Additionally
    - i. Completion of check list
    - ii. Findings
    - iii. Corrections, referrals or plans for either
    - iv. Inability to complete corrections or referrals and reason

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### MEDICATION AUDIT

Initial Date: August 28, 2020

Revised Date: Section 11-28

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for the minimum elements of a medication audit and when it should be performed.

- I. Indications
  - a. CIP Encounter
- II. Contraindications
  - a. None
- III. Equipment
  - a. MCA approved medication audit checklist which will include:
    - i. Medication expiration dates
    - ii. Dispensing method of medications that works for the patient
    - iii. Barriers to obtaining medications
    - iv. Questions or concerns patient has regarding medications which will be forwarded to PCP or referring physician.

#### IV. Procedures

- a. Perform medication audit according to referring physician directions or MCA approved medication audit checklist when physician orders are not present.
- b. Findings that present threats to the patient's immediate health and well-being must be reported to the referring physician prior to the conclusion of the visit.

#### V. Documentation see CIP Documentation protocol

- a. Additionally
  - i. Completion of medication audit
  - ii. Findings
  - iii. Name of provider notified of the discrepancy along with date and time of notification
  - iv. Course of action determined appropriate by online medical control if applicable

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Michigan COMMUNITY INTEGRATED PARAMEDICINE

### Procedure Protocol FEEDING TUBES

Initial Date: November 13, 2020

Revised Date: Section 11-29

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to maintain a percutaneous tract into the stomach or a nasogastric tube through evaluation of efficacy and either rectifying or making a referral for ineffective tracts.

Aliases: Feeding Tubes, NG tubs, PEG tubes

- I. Indications
  - a. Complaints including blockage, damage or need for replacement
- II. Contraindication
  - a. Signs of infection or active bleeding
- III. Equipment
  - a. 10 ml syringe
  - b. Warm water or carbonated beverage such as diet cola
  - c. Approved de-clogging device designed for the tube.
- IV. Procedure
  - a. Identify the type of feeding tube.
  - b. Examine for patency, functionality, and placement.
  - c. If there is evidence of blockage, using sterile technique flush the tube using a 10 ml syringe and water or carbonated beverage.
    - i. If unable to flush use carbonated beverage and let it sit for 5-10 minutes and reattempt flushing.
  - d. If unable to establish good flow and the tube is in place, consider making arrangement for replacement.
  - e. Nasogastric tube removal (optional)
    - i. Obtain medical direction prior to procedure
    - ii. Position patient a minimal of a 30-degree incline from supine to prevent aspiration
    - iii. Discontinue gastric suction
    - iv. Flush the tube with a small bolus of air to clear any remaining gastric contents
    - v. Remove securement device
    - vi. Fold over or clamp the proximal end of the tube to prevent backflow of gastric contents
    - vii. Direct patient to hold the breath to close the epiglottic and withdraw the tube gently and steadily.
    - viii. When the distal end of the tube reaches the nasopharynx, it can be pulled quickly
    - ix. Inspect the tube to ensure it is intact
  - f. Replacement of damaged percutaneous tube in a well-established tract (optional)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Page 1 of 2



#### FEEDING TUBES

Initial Date: November 13, 2020

Revised Date: Section 11-29

- i. Indications
  - a. Inadvertent removal of a tube
- ii. Contraindications
  - 1. Initial gastrostomy placed less than 2 months ago
  - 2. Tube has been out of place for more than 24 hours
- iii. Procedure
  - 1. Consider analgesics
  - 2. Utilize sterile technique
  - 3. Insert largest appropriate replacement tube (urinary catheter)
- g. Concerns that present threats to the patient's immediate health and well-being must be reported to the referring physician prior to the conclusion of the visit.
- V. Documentation see CIP Documentation protocol
  - a. Additionally (if applicable)
    - i. Results of attempts to flush tubes
    - ii. Removal of NG tubes, tube intact and patient reaction
    - iii. Replacement of percutaneous tract tube, confirmation of placement and measurements

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### URINARY CATHETER

Initial Date: November 19, 2020

Revised Date: Section 11-30

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to evaluate efficacy, rectify issues or make appropriate referrals for ineffective urinary catheters. Allow placement of urinary catheters for patients with known recurring urinary retention.

**Aliases:** Foley, cath, suprapubic catheter, indwelling catheter, urinary catheter, sterile technique = aseptic technique.

- I. Indications for urinary catheter care
  - a. blockage or damage of the catheter
  - b. physician ordered replacement
  - c. need for removal
  - d. need for removal and reinsertion
  - e. catheterization for relief of urinary retention
  - f. Consult with referring physician prior to initial placement of a urethral catheter unless it is explicitly written in the physician's orders.
- II. Contraindications
  - a. Recent external trauma to pelvis
- III. Equipment
  - a. Appropriate size urethral catheter (5Fr-26Fr)
  - b. Collection bag
  - c. Syringe (10ml, 20ml or 30ml)
  - d. Lubricant
  - e. Lidocaine Jelly 2%
  - f. Sterile water
  - g. Sterile field kit
- IV. Procedures
  - a. Flushing of an indwelling catheter
    - i. Identify the type of catheter.
    - ii. Examine the catheter for patency, functionality, and placement.
    - iii. If there is evidence of blockage, using sterile technique flush the tube using a 10-30 ml syringe using sterile water at room temperature.
    - iv. If unable to establish good flow, the catheter is non-functional, damaged or has become displaced consider removal and replacement.
  - b. Removal of urethral or suprapubic catheter
    - i. Empty bag of urine
    - ii. Remove all fluid from balloon
    - iii. Gently remove
    - iv. Note length of the tube section that was inserted
  - c. Placement or replacement of urethral catheter

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### URINARY CATHETER

Initial Date: November 19, 2020

Revised Date: Section 11-30

- i. Obtain medical direction prior to <u>initial</u> placement of an indwelling urethral catheter
- ii. Prepare sterile field, utilize sterile technique
- iii. Check balloon for patency
- iv. Generously coat the distal portion (2-5 cm) of the catheter with lubricant and/or 2% Lidocaine Jelly 5 to 30 ml for males and 3-5 ml for females.
- v. Females, separate labia using non-dominant hand. For males, hold the penis with the non-dominant hand.
- vi. Maintain hand position until preparing to inflate balloon.
- vii. Using dominant hand to handle forceps, cleanse peri-urethral mucosa with cleansing solution. Cleanse anterior to posterior, inner to outer, one swipe per swab, discard swab away from sterile field.
- viii. Pick up catheter with gloved (and still sterile) dominant hand. Hold end of catheter loosely coiled in palm of dominant hand.
- ix. In the male, lift the penis to a position perpendicular to patient's body and apply light upward traction (with non-dominant hand)
- x. Identify the urinary meatus and gently insert until 1 to 2 inches beyond where urine is noted
- xi. Inflate balloon, using correct amount of sterile liquid (usually 10 cc but check actual balloon size)
- xii. Gently pull catheter until inflation balloon is snug against bladder neck
- xiii. Connect catheter to drainage system
- xiv. Secure catheter to abdomen or thigh, without tension on tubing
- xv. Place drainage bag below level of bladder
- xvi. Evaluate catheter function and amount, color, odor, and quality of urine
- xvii. Remove gloves, dispose of equipment appropriately, wash hands
- xviii. Document size of catheter inserted, amount of water in balloon, patient's response to procedure, and assessment of urine
- d. Replacement of existing suprapubic catheter
  - i. Prepare sterile field, utilize sterile technique
  - ii. Check balloon for patency
  - iii. Clean and lubricate the insertion site area
  - iv. Insert the catheter into the suprapubic site the same distance as the catheter removed.
  - v. Inflate balloon, using correct amount of sterile liquid (usually 10 cc but check actual balloon size)
  - vi. Gently pull catheter until inflation balloon is snug against bladder neck
  - vii. Connect catheter to drainage system
  - viii. Secure catheter to abdomen or thigh, without tension on tubing
  - ix. Place drainage bag below level of bladder
  - x. Evaluate catheter function and amount, color, odor, and quality of urine
  - xi. Remove gloves, dispose of equipment appropriately, wash hands
  - xii. Document size of catheter inserted, amount of water in balloon, patient's response to procedure, and assessment of urine

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2025 MCA Implementation Date: 1/31/2025

Protocol Source/References:

oard Approval Date: 11/12/2025 Page **2** of **3** 



URINARY CATHETER

Initial Date: November 19, 2020

Revised Date: Section 11-30

V. Concerns that present threats to the patient's immediate health and well-being must be reported to the referring physician at the conclusion of the visit, all other concerns within 24 hours.

- VI. Documentation see CIP Documentation protocol
  - a. Additionally:
  - i. Color, odor, and quantity of urine when applicable

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2025 MCA Implementation Date: 1/31/2025



#### OSTOMY BAG REPLACEMENT

Initial Date: December 14, 2020

Revised Date: Section 11-31

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to change an ostomy bag and/or evaluate efficacy and make a referral for ineffective ostomies.

Aliases: Colostomy, ileostomy.

- Indications
  - a. Need for bag replacement or evaluation for complaints including blockage, damage, or signs of infection.
- II. Equipment
  - a. One or two-piece ostomy appliance
- III. Procedure for bag change
  - a. Examine the ostomy site for herniation, bleeding, or signs of infection.
    - i. If signs of herniation, bleeding or infection are present contact referring physician for orders.
  - b. Identify ostomy appliance as either a one piece or a two-piece appliance.
  - c. Measure the ostomy site if it is less than 6 weeks old.
  - d. Remove per manufacturer's directions.
  - e. Remove excess stool from skin
  - f. Prepare skin/site for replacement of flange/wafer if applicable.
  - g. Place following manufacturer's directions
  - h. Concerns that present threats to the patient's immediate health and well-being must be reported to the referring physician at the conclusion of the visit, all other concerns within 24 hours.
- IV. Documentation see CIP Documentation protocol

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



NASAL PACKING PLACEMENT AND REMOVAL

Initial Date: November 13, 2020

Revised Date: Section 11-32

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to place and/or remove anterior nasal packing as approved by the MCA.

Aliases: Rhino rockets, nasal tampons

- I. Anterior Nasal Packing Placement (optional)
  - a. Indications
    - i. Nasal packing for nosebleeds that have not been controlled by lesser measures see CIP Non-Traumatic Nosebleed protocol
  - b. Contraindications
    - i. Nosebleeds caused by trauma
  - c. Equipment
    - MCA approved manufactured nasal packing that includes manufacturer recommendations for placement and usage
  - d. Procedure
    - i. Obtain medical direction prior to procedure
    - ii. Follow manufacturer's directions for placement
    - iii. Remain with patient for 30 minutes to assure bleeding has stopped
      - 1. If bleeding has not stopped activate 9-1-1 for transport to an emergency department
    - iv. Arrange for follow-up with PCP within 24-48 hours.
      - 1. If follow-up with PCP cannot be made withing 24-48 hours schedule CIP follow-up within 24 for nasal packing removal.
  - e. Documentation see CIP Documentation protocol
- II. Anterior Nasal Packing Removal (optional)
  - a. Indications
    - i. Nasal packing has been in place for 24-48 hours
  - b. Contraindications
    - i. Active bleeding
  - c. Equipment
    - i. Syringe
  - d. Procedure
    - i. Obtain medical direction prior to procedure
    - ii. Evaluate for presence of balloon
    - iii. Deflate balloon completely with appropriate size syringe
    - iv. Gently pull the strings attached to the packing until packing is completely removed
    - v. Observe patient for 5 minutes to ensure bleeding does not reoccur.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



NASAL PACKING PLACEMENT AND REMOVAL

Initial Date: November 13, 2020

Revised Date: Section 11-32

1. If bleeding reoccurs see CIP Non-Traumatic Nosebleed protocol

e. Documentation see CIP Documentation protocol

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### SPECIMEN COLLECTION

Initial Date: October 23, 2020

Revised Date: Section 11-33

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to obtain and transport specimen at the request of a health care provider as approved by the MCA

Aliases: labs, strep test, swab test

- Indications
  - a. Order from a clinician requesting specimen collection to be obtained and transported to the appropriate testing facility when a patient has a barrier to submitting specimens in a timely manner.
  - b. Specimen collection for the purpose of point of care testing.
- II. Procedure
  - a. For <u>all</u> procedures accompanied by a physician's order.
    - i. Review order for special instructions prior to collecting the specimen
    - ii. Label with the patient's name, date of birth, and additional information required for the specific specimen (source, date, time) or required by the MCA or specimen testing facility.
    - iii. Complete appropriate lab paperwork.
    - iv. Transport sample in a biohazard bag or follow clinician's order for shipping.
- Lab Draw (optional)
- i. Considerations: Patients who are on blood thinners may require prolonged direct pressure after blood draw. Equipment
  - 1. Appropriate needle
  - 2. Rainbow tubes
- ii. Procedure
  - 1. Select an appropriate site and using universal precautions cannulate the vein.
  - 2. Blood tubes should be collected in the order of red, green, purple, pink and blue.
- c. 🔲
- Urine Specimen (optional)
- i. Equipment
  - 1. Urine specimen cup
  - 2. wipes
- ii. Procedure
  - 1. Obtain sample through method ordered (clean catch, foley bag, etc.)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



### Michigan COMMUNITY INTEGRATED PARAMEDICINE

### Procedure Protocol SPECIMEN COLLECTION

Initial Date: October 23, 2020

Revised Date: Section 11-33

d. Nasal Swab

- i. Equipment appropriate swabs for specific test
- ii. Procedure
  - 1. Place patient in seated position
  - 2. Tilt patient's head back slightly to visualize nasal passages
  - 3. Gently insert swab along nasal septum, just above the floor of the nasal passage, to the nasopharynx
    - a. Stop when resistance is met & do not force the swab further
    - b. If resistance is detected, pull back slightly and try reinserting at a different angle, closer to the floor of the nasal canal
    - c. The swab should reach a depth equal to the distance from the nostrils to the outer opening of the ear
  - 4. Rotate swab several times, remaining in the passage for 10 seconds
  - 5. Gently removed swab while rotating
  - Place swab into collection tube according to directions and prior to breaking the stick
  - 7. Secure lid on the tube
- e. 🔲

#### **Throat Swab**

- i. Equipment appropriate swabs for specific test
- ii. Procedure
  - 1. Place patient in seated position
  - 2. Tilt patient's head back, instruct them to open their mouth and stick out their tongue
  - 3. Use a wooden tongue depressor to hold the tongue in place
  - 4. Visualize the posterior nasopharynx and tonsillar arches
  - 5. Without touching the side of the mouth, insert the swab reaching the posterior nasopharynx and tonsillar arches wiping the swab on the area
  - Place swab into collection tube according to directions and prior to breaking the stick
  - 7. Secure the lid on the tube
- III. Documentation see CIP Documentation protocol
  - a. Additionally: testing procedure used and results if applicable

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### POINT OF CARE TESTING FOR BLOOD ANALYSIS

Initial Date: October 23, 2020

Revised Date: Section 11-34

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to perform advanced point of care testing at patient's side with a CLIA waived device that performs blood analysis. This protocol was designed around the use of the Abbot i-STAT system and Piccolo Xpress system. Always follow manufacturer instructions.

**Aliases:** Handheld blood analyzer, portable clinical analyzer, i-STAT, Piccolo

- I. Indications
  - a. Physician's order
  - b. CIP Patients who require point of care testing to guide treatment.
- II. Contraindications
  - a. Not CLIA waived
- III. Equipment
  - a. CLIA waived point of care testing device with appropriate CLIA waived cartridges for testing.
  - b. Appropriate equipment for specific device.
- IV. Procedure
  - a. Obtain appropriate blood sample.
  - b. Follow device's instructions for use.
- V. Documentation see CIP Documentation protocol
  - a. Additionally: cartridges utilized and test results

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### SUTURE REMOVAL

Initial Date November 13, 2020 Revised Date:

Section 11-35

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to safely remove sutures and/or staples as approved by the MCA.

Aliases: Stitches, staples

- I. Indications
  - a. Request from a clinician to remove a known type of suture
- II. Contraindications
  - a. Signs of wound complications or infection
- III. Equipment
  - a. Forceps
  - b. Suture scissors
  - c. Staple remover
  - d. Sterile gauze
  - e. Sterile 0.9% sodium chloride solution
  - f. Sterile wound strips
- IV. Procedure
  - a. Plain suture removal (optional)
    - i. Gently grasp the knot or the tail with forceps and raise it slightly
    - ii. Place the curved tip of the suture scissors directly under the knot or on the side, close to the skin
    - iii. Gently cut the suture and pull it out with the forceps
    - iv. Make sure all suture material is removed and placed on clean gauze
    - v. Remove alternate sutures
    - vi. Assess the wound for dehiscence (edges of the wound do not meet)
      - 1. Absence of dehiscence
        - a. Remove remaining sutures
        - b. Apply sterile wound strips to prevent dehiscence
      - 2. Presence of dehiscence
        - a. Do not continue to remove sutures
        - b. Cover wound with sterile gauze saturated with sterile 0.9% sodium chloride solution
        - c. Contact physician see CIP Medical Direction protocol
  - b. Staple removal (optional)
    - i. Place the lower jaw of the remover under a staple
    - ii. Squeeze the handles completely to close the device bending the staple in the middle and pulling the edges of the staple out of the skin
    - iii. Gently move the staple away from the incision site when both ends are visible
    - iv. Hold the staple remover over a sharps container, relax pressure on the handles, let the staple drop into the sharps container

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Page **1** of **2** 



SUTURE REMOVAL

Initial Date November 13, 2020 Revised Date:

Section 11-35

- v. Remove alternate staples
- vi. Assess the wound for dehiscence (edges of the wound do not meet)
  - 1. Absence of dehiscence
    - a. Remove remaining staples
    - b. Apply sterile wound strips to prevent dehiscence
  - 2. Presence of dehiscence
    - a. Do not continue to remove staples
    - b. Cover wound with sterile gauze saturated with sterile 0.9% sodium chloride solution
    - c. Contact physician see CIP Medical Direction protocol
- V. Documentation see CIP Documentation protocol
  - a. Additionally:
    - i. Date and time of removal
    - ii. Number of sutures or staples removed
    - iii. Dressings or adhesive wound strips applies
    - iv. Appearance of the incision

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



OTOSCOPE

Initial Date: November 13, 2020

Revised Date: Section 11-36

**Purpose:** Provide guidelines for CIP paramedics to utilize an otoscope or disposable speculum for patient evaluation.

#### Aliases: speculum

- I. Indications
  - a. Need for visualization of the eardrum
- II. Contraindications
  - a. None
- III. Equipment
  - a. Otoscope
  - b. Otoscope with disposable specula (eartip)
- IV. Procedure
  - a. Adult positioning
    - i. Use otoscope with largest ear speculum that the ear canal will accommodate
    - ii. Position patient's head and neck upright
    - iii. Grasp auricle firmly and gently, pull upwards, backward and slightly away from the head
    - iv. Hold otoscope handle between thumb and fingers and brace hand against patient's face
    - v. Insert speculum into ear canal, directing it somewhat down and forward and through hairs
  - b. Child positioning
    - i. Child may sit up or lie down
    - ii. Hold otoscope with handle pointing down toward child's feet while pulling up on auricle
    - iii. Hold the head and up on auricle with one hand while holding otoscope with the other hand
    - iv. Insert speculum into ear canal, directing it somewhat down and forward and through hairs
  - c. Inspection for both adult and child
    - Inspect ear canal noting discharge, foreign bodies, redness and/or swelling
    - ii. Inspect eardrum noting color and contour and perforations
- V. Documentation see CIP Documentation protocol
  - a. Additionally:
    - i. Eardrum color, translucency, and presence or absence of swelling or perforation.
    - ii. Ear canal discharge, foreign bodies, redness and/or swelling

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



#### PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) ACCESS

Initial Date: October 23, 2020

Revised Date: Section 11-37

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for the use of PICC lines.

Aliases: PICC

- I. Peripherally Inserted Central Catheters (PICC
  - a. Description: PICC lines are long catheters inserted through a vein in the arm, leg or neck with the terminal end positioned in the superior vena cava, inferior vena cava, or the proximal right atrium. PICC lines are used for long duration access generally up to 6 months.
  - b. CIP Uses: Accessing for medications, antibiotics, parenteral nutrition, and blood draws.
  - c. Indications
    - i. Accessing for blood draws or administration of fluids and/or medications
    - ii. Maintenance including flushing, dressing change and evaluation of insertion site
  - d. Contraindications
    - i. Has not been used and confirmed
    - ii. Suspicion it is not patent
    - iii. Signs of infection at site
  - e. Equipment
    - i. Saline Flush (x2)
    - ii. 10 cc syringe (x2)
  - f. Procedure
    - i. Appropriate PPE and use sterile technique
    - ii. Evaluate the site for redness, pain, exudate, and the arm for swelling, pain and stiffness
    - iii. Flush the PICC line with 10ml of NS
    - iv. Administer medications and/or fluids a prescribed or draw blood for labs
    - v. Flush the PICC line with 10ml NS
- II. Documentation see CIP Documentation protocol

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### VACCINATIONS

Initial Date: October 23, 2020

Revised Date: Section 11-38

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for the administration of vaccinations as approved by the MCA.

Aliases: Immunizations

- Indications
  - a. Order from a clinician requesting the administration of a vaccination
  - b. Participation in mass immunization settings
- II. Vaccinations eligible for administration by CIP paramedics as approved by the MCA include:
  - a. Chickenpox (Varicella)
  - b. Diphtheria
  - c. Flu (Influenza)
  - d. Hepatitis A
  - e. Hepatitis B
  - f. Hib (Haemophilus influenzae type b)
  - g. HPV (Human Papillomavirus)
  - h. Measles
  - i. 

    Meningococcal
  - j. Mumps
  - k. Pneumococcal
  - I. Polio (Poliomyelitis)
  - m. Rotavirus
  - n. Rubella (German Measles)
  - o. Shingles (Herpes Zoster)
  - p. Tetanus (Lockjaw)
  - q. Whooping Cough (Pertussis)
  - r. COVID 19 when available
- III. Contraindications
  - a. Allergies noted in pre immunization screening
- IV. Equipment
  - a. Vaccine
  - b. Appropriate delivery device
- V. Procedure
  - Timing and dosing of immunizations will be determined by the PCP and/or public health department
  - b. Pre immunizations screening must be done prior to administration of the vaccination

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



**VACCINATIONS** 

Initial Date: October 23, 2020

Revised Date: Section 11-38

> c. Vaccinations may be administered via IM, SQ or intranasal route as appropriate for the specific vaccination

> d. Verify Michigan Care Improvement Registry (MCIR) documentation

Documentation see CIP Documentation protocol VI.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### NALOXONE LEAVE BEHIND

Initial Date: November 19, 2020

Revised Date: Section 11-39

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** Provide guidelines for CIP paramedics to leave a Naloxone kit with patients who are being evaluated and cared for due to a narcotic substance use disorder.

Aliases: Leave behind, Narcan kit

- I. Indications
  - a. Patient is enrolled in a CIP program
- II. Contraindications
  - a. Under the age of 18
- III. Equipment
  - a. Prepackaged naloxone kit see CIP Naloxone Medication Kit Contents and Distribution protocol
- IV. Procedure
  - a. Provide naloxone kit to patient
  - b. Educate patient and support persons on use of naloxone kit
    - i. Demonstrate administration with dummy intranasal device and water
      - 1. Allow patient to express water from intranasal device
    - ii. Discuss the importance of respiratory support
    - iii. Discuss the importance of initiating a 9-1-1 response
    - iv. Discuss the risks of an opioid medication half-life potentially being longer than the duration of naloxone
    - v. Discuss the risks of a single does of naloxone being insufficient for full reversal
- V. Documentation see CIP Documentation protocol

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



# Michigan COMMUNITY INTEGRATED PARAMEDICINE Procedure Protocol

NALOXONE MEDICATION KIT CONTENTS AND DISTRIBUTION PROCEDURE (OPTIONAL)

Initial Date: November 19, 2020

Revised Date: Section 11-41

#### Naloxone Medication Kit Contents and Distribution Procedure

- I. Medications and supplies for naloxone kits will be supplied by member facilities within the MCA.
- II. Assembly, labeling, and access to kits will be done according to the **Pharmacy**, **Drug Box and IV Supply Exchange Procedure**.
- III. Overdose Medication Kit Contents List

Medication / Item	Concentration	Packaging	Quantity
Naloxone (Narcan)	4mg / spray	Nasal Spray	1
MDHHS Safety Advice			
for Patient and Family			1
Members Card			
Resuscitation			1*
Face shield*			*(MCA Optional)
Replacement Form			1
Local Treatment			1
Resources Form			'

#### IV. Procedure

- A. Each participating EMS Agency will stock each of its licensed vehicles with 2 Naloxone Medication Kits. After deployment, the naloxone medication kit will be replaced within 24 hours at the assigned stocking hospital pharmacy.
- B. Kits will be stored on the EMS vehicle in a secure way, not accessible to the public.
- C. Deployment of a Naloxone Medication Kit will be documented the patient care record and uploaded to the Michigan EMS Information System.
- D. The replacement/use form will be completed and returned to the designated hospital pharmacy for dispensing of a replacement Naloxone Kit.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### CIP PATIENT GENERAL ASSESSMENT AND CARE

Initial Date: October 23, 2020

Revised Date: Section 11-50

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for evaluation and care of patients under a CIP program.

- I. Prior to initiation of patient contact review the following when available:
  - a. Patient complaint/illness/reason for visit
  - b. Available previous pertinent patient care records
  - c. Physician's orders
  - d. Protocols pertinent to patient condition, patient complaint or physician's orders as these will contain additional requirements and suggestions for vital signs, history, diagnostics, and patient counseling/education.
- II. Evaluate for presence of potentially life-threatening medical needs upon arrival and monitor continuously throughout care.
  - a. <u>Potentially life-threatening</u> medical needs exist, initiate 9-1-1 response see CIP Medical Direction protocol
    - Suspend CIP call and utilized local MCA protocols as necessary
- III. Verify patient complaints and history with patient and other available sources.
  - a. Sources may include but are not limited to referring agency, referring physician, referring EMS unit or family
- IV. Perform a physical exam pertinent to patient's complaint or condition.
- V. Perform diagnostic studies as indicated by patient complaint/illness/reason for visit.
  - a. Diagnostics: blood glucose level, ECG, ETCO2, I-STAT, other studies as available.
- VI. Determine patient disposition:
  - a. Transport to the emergency department
    - a. Conditions in which transport to the emergency department should be considered:
      - 1. Altered level of consciousness
      - 2. Potential sepsis
      - 3. Vital sign compromise or instability
    - b. Procedure
      - 1. Activate 9-1-1 response
      - 2. Remain with patient until transporting unit arrives
      - 3. Notify physician of transport see CIP Medical Direction protocol

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



CIP PATIENT GENERAL ASSESSMENT AND CARE

Initial Date: October 23, 2020

Revised Date: Section 11-50

- 4. Document see CIP Documentation protocol
- b. On-scene treatment indicated:
  - a. Initiate care: see applicable Care (treatment) and/or
     Complaint (treatment) protocol(s) seeking medical direction as indicated per protocol.
    - All on-scene medical treatment must have standing orders from the referring physician or direct online medical control.
  - **b.** Evaluate patient response to treatment and determine patient disposition (go back to VI).
- c. On-scene treatment not indicated or completed with desired results:
  - a. Fall Risk Reduction Assessment see CIP Fall Risk Reduction Assessment protocol
  - b. Social Determinants of Health Assessment see CIP Social Determinants of Health protocol
  - c. Medication Audit see CIP Medication Audit protocol
  - d. Patients without a primary care provider and/or not enrolled in the CIP program see CIP Program Enrollment protocol and see CIP Medical Direction protocol
  - e. Counsel/educate patient:
    - 1. Pathophysiology of disease/complaint
    - 2. When to call a health care provider
    - 3. Condition/complaint specific education see applicable Care (treatment) and/or Complaint (treatment) protocol(s)
  - f. Develop a care plan/service plan for the patient see CIP Patient Service Plan/Care Plan protocol
- VII. Document see CIP Documentation protocol.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



DIABETIC CARE

Initial Date: November 19, 2020

Revised Date: Section 11-51

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with Diabetes.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician.
  - a. Vitals: BGL
  - b. History: Last oral intake, diet, medication changes and compliance
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
  - Use of patient's prescribed medications beyond the parameters of the prescription must have direct consultation with the referring physician prior to administration
  - d. Oral high caloric fluid
  - e. Oral glucose gel or tablets
  - f. IV Fluid bolus of 0.9% NS maximum dose 2L
- IV. On-scene education and suggested support sources may include:
  - i. Diabetes Self-Management Education

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



ASTHMA CARE

Initial Date: November 19, 2020

Revised Date: Section 11-52

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with Asthma.

#### I. Follow CIP Patient General Assessment and Care protocol

- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals: SpO2, work of breathing
  - b. History:
    - i. Frequency, duration, and triggers of DIB
    - ii. Previous and recent episodes requiring treatment
    - iii. Use of medications (short acting and long-acting corticosteroids, etc.)
    - iv. Spirometry, peak flow, capnography
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene education and suggested support sources may include
  - a. Review patient's current history including frequency of symptoms with rest, with activity and with sleep
  - b. Review exacerbating factors including viral exposure, allergen exposure, exercise, cold air, tobacco smoke, chemical irritants, etc.
  - c. Observe the home to identify exacerbating factors
  - d. Review devices used by the patient including short/long-acting medications and MDI/continuous nebulizer devices
  - e. Review when to call health provider
  - f. National Certified Asthma Educator referral

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### CHRONIC OBSTRUCTIVE PULMONDARY DISEASE CARE

Initial Date: November 19, 2020

Revised Date: Section 11-53

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with COPD.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals: SpO2, work of breathing
  - b. History:
    - i. History of previous and recent episodes requiring treatment
    - ii. Use of medications (short acting and long-acting corticosteroids, etc.)
  - c. Diagnostics:
    - i. Spirometry, peak flow, capnography
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene education and suggested support sources may include:
  - a. Review patient's current history including frequency of symptoms with rest, with activity and with sleep
  - b. Review exacerbating factors including viral exposure, allergen exposure, exercise, cold air, tobacco smoke, chemical irritants, etc.
  - c. Observe the home to identify exacerbating factors
  - d. Review devices used by the patient including short/long-acting medications and MDI/continuous nebulizer devices

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### CONGESTIVE HEART FAILURE CARE

Initial Date: November 19, 2020

Revised Date: Section 11-54

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with CHF.

#### I. Follow CIP Patient General Assessment and Care protocol

- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals:
    - i. Weight
    - ii. Blood pressure with systolic and diastolic evaluation
    - iii. SpO2
  - b. History:
    - i. Weight and blood pressure history and trends
    - ii. Activity tolerance
    - iii. Sleeping position
    - iv. Recent DIB requiring treatment
    - v. Medication use (diuretics, respiratory)
    - vi. Spirometry, peak flow, capnography
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene education and suggested support sources may include:
  - a. Salt and fluid intake discussion/counseling
  - b. Review of proper device care and use: oxygen, diuretics, CPAP, and other medications being used for maintenance.

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol CHRONIC HYPERTENSION CARE

Initial Date: November 19, 2020

Revised Date: Section 11-55

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with chronic hypertension.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals:
    - i. Manual and automated blood pressure
  - b. History:
    - i. Diet
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
  - c. Use of patient's prescribed medications beyond the parameters of the prescription must have direct consultation with the referring physician prior to administration
- IV. On-scene education and suggested support sources may include:
  - a. Salt and fluid intake discussion/counseling

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### **Treatment Protocol**

POST MYOCARDIAL INFARCTION OR CARDIAC INTERVENTION CARE

Initial Date: November 19, 2020

Revised Date: Section 11-56

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with post MI or cardiac intervention care.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/physical examination
    - i. Evaluation of procedure specific incisions/wounds/dressings
  - b. History:
    - Enrollment and compliance with cardiac rehab services
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene education and suggested support sources may include:
  - a. Cardiac rehab services referrals

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol POST ORTHOPEDIC SURGICAL INTERVENTION CARE

Initial Date: November 19, 2020

Revised Date: Section 11-57

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with post orthopedic surgical interventions.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/physical examination
    - i. Wound evaluation (redness, unexpected drainage, streaking)
    - ii. Pulse, motor, sensation evaluation
    - iii. Durable Medical Equipment (DME) use
  - b. History:
    - i. DME access and use
    - ii. Activities of Daily Living (ADL) education and compliance
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene interventions and additional care may include:
  - a. Suture Removal see CIP Suture Removal protocol (optional)
  - b. Wound Care see CIP Wound Care protocol (optional)
- V. On-scene education and suggested support sources may include:
  - a. ADL assistance

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



POST STROKE CARE

Initial Date: November 19, 2020

Revised Date: Section 11-58

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with post stroke.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals:
    - i. Blood pressure both automated and manual
    - ii. Stroke scale re-evaluation
  - b. History
    - i. Use of memory aids and activity of daily living aids
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- IV. On-scene education and suggested support sources may include:
  - a. Support groups for both patient and family
  - b. Use of DME
  - c. Memory aids
  - d. ADL assistance

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol PRENATAL CARE

Initial Date: November 19, 2020

Revised Date: Section 11-59

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients and families who are pregnant.

#### I. Follow CIP Patient General Assessment and Care protocol

- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals:
    - a. Blood pressure both manual and automated
    - b. Weight
    - c. Fetal heart tones
    - d. Fundal height
  - b. History:
    - a. Substance use current and past (tobacco, illicit, use and/or abuse of prescribed or non-prescribed)
    - b. Domestic violence current and past
    - c. Prenatal care history/compliance
    - d. Vaginal bleeding
    - e. Gestational diabetes
    - f. Pregnancy induced hypertension or preeclampsia
    - g. Postpartum depression
  - c. Diagnostics:
    - a. Depression screening
- III. Care will not include vaginal examinations with the exception of impending delivery or hemorrhage
  - a. Cervical and pelvic examinations to check for dilation are not permitted
- IV. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Assist with patient's prescribed home medications that are not included in standard EMS treatment protocols
- V. On-scene education and suggested support sources may include:
  - a. Nutrition and supplements
  - b. Breastfeeding resources
  - c. Postpartum depression support
  - d. Newborn safety including:
    - a. Safe sleeping recommendations/resource
    - b. Car seat safety
    - c. Infant CPR
    - d. Shaken baby syndrome

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



MOTHER AND INFANT - POST PARTUM CARE

Initial Date: November 19, 2020

Revised Date: Section 11-60

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating mothers and infants post- partum.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/physical assessment:
    - i. Mother
      - 1. Blood pressure both manual and automated
      - 2. Weight
    - ii. Infant
      - 1. Weight
      - 2. Temperature
      - 3. Heart Rate
      - 4. Jaundice presence

### VISUAL ASESSMENT-KRAMER'S RULE




Table 1. Visual Assessment of Neonatal Jaundice (Kramer's rule)

	Level	Range of Serum Bilirubin	
Area of the Body		µmol/L	mg/dL
Head and neck	1	68 - 133	4-8
Upper trunk (above umbilicus)	2	85 - 204	5 - 12
Lower trunk and thighs (below umbilicus)	3	136 - 272	8 - 16
Arms and lower legs	4	187 - 306	11 - 18
Palms and soles	5	≥306	≥18

Kramer's rule describes the relationship between serum bilirubin levels & the progression of skin discolouration

20

- a. Adequacy of feeding
- b. Wakefulness/waking to feed
- c. Stool transition

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



### Treatment Protocol MOTHER AND INFANT – POST PARTUM CARE

Initial Date: November 19, 2020

Revised Date: Section 11-60

- b. History
  - i. Mother
    - 1. Feelings of depression
    - 2. Eating, sleeping and self-care
    - 3. Complications with pregnancy
  - ii. Infant
    - 1. Feeding habits
- c. Environment
  - i. Safe sleeping arrangement for infant
  - ii. PEAT scale
- d. Diagnostics:
  - i. Depression screening
- III. Consider transport to the emergency department for the following:
  - a. Infant temperature > or equal to 100.4 degrees OR < 96 degrees Fahrenheit as taken rectally.
  - b. Infant HR > 200.
  - c. Infant current weight less than birth weight minus 10%.
  - d. Maternal hemorrhage (use of greater than one maxi pad per hour)
  - e. Maternal signs of anemia with or without signs of external hemorrhage
  - f. Maternal signs of eclampsia
- IV. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
- V. On-scene education and suggested support sources may include:
  - a. Nutrition and supplements
  - b. Breastfeeding resources
  - c. Postpartum depression support
  - d. Newborn safety including:
    - i. Safe sleeping recommendations/resource
    - ii. Car seat safety
    - iii. Infant CPR
    - iv. Shaken baby syndrome

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### DIAGNOSED SLEEP APNEA CARE

Initial Date: November 19, 2020

Revised Date: Section 11-61

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with diagnosed sleep apnea.

Aliases: Obstructive Sleep Apnea

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/physical assessments/social assessments
    - i. SpO2
    - ii. Weight/BMI
    - iii. Proper fit of mask
    - iv. Quality of life score utilizing test used prior to diagnosis
  - b. History:
    - i. Sleep habits
    - ii. Use of sleep aids (OTC, prescription)
    - iii. Alcohol and drug use both recreational and self-medicating
  - c. Diagnostics:
    - i. Capnography
- III. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
- IV. On-scene interventions may include:
  - a. Adjustment of CPAP setting per referring physician's orders
- V. On-scene education and suggested support sources may include:
  - a. Equipment maintenance and use

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### reatment Protoco WOUND CARE

Initial Date: December 14, 2020

Revised Date: Section 11-62

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with wounds.

#### Aliases:

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/physical assessment:
    - i. Categorize, stage and measure wound when applicable

Stage	Description
Stage I	Non-blanchable erythema of intact skin
Stage II	Partial thickness skin loss; ulcer extends down to epidermis and/or dermis
Stage III	Full thickness skin loss; ulcer extends down to subcutaneous fat and fascia
Stage IV	Full thickness skin loss with extensive destruction and tis- sue necrosis; ulcer extends down to muscle, bone, ten- don, or joint capsule

- ii. Location and extent of skin changes
- Redness, drainage, weeping, ascending redness, warmth of skin, tract formation
- iv. Presence of pain
- b. History:
  - i. Mechanism and duration of wound
- III. On scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
- IV. On-scene interventions may include:
  - a. D Suture Removal **see CIP Suture Removal protocol** (optional)
  - b. Decontamination and cleansing of wound
  - c. Wound closure utilizing wound closure strips
  - d. Wound dressing
- V. On-scene education and suggested support sources may include:
- VI. Counsel/Educate
  - a. ADL precautions

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



Initial Date: December 14, 2020

Revised Date: Section 11-62

b. Self-administered wound care

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### SUBSTANCE USE DISORDER CARE

Initial Date: November 19, 2020

Revised Date: Section 11-63

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide additional guidelines beyond the CIP General Assessment and Care for evaluating, caring for and educating patients with Substance Use Disorder.

- I. Follow CIP General Assessment and care protocol
- II. Obtain additional vital signs, history, and diagnostics pertinent to condition and/or as ordered by physician which may include:
  - a. Vitals/examinations:
    - i. Site infections/wounds
    - ii. COWs assessment/score
    - iii. CIWA assessment/score
    - iv. Signs of substance intoxication
    - v. Oral health
    - vi. Hygiene
  - b. History:
    - i. Evaluate risks for concurrent polysubstance use
    - ii. Use history for prescribed medications and illicit substances
    - iii. Intervention history
    - iv. Immunization status
- III. On scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
- IV. On scene interventions may include:
  - a. Vaccinations see CIP Vaccination protocol (optional)
  - b. Wound Care see CIP Wound Care protocol (optional)
  - c. Naloxone Leave Behind see CIP Naloxone Leave Behind protocol (optional)
  - d. Medication Assisted Therapy (MAT) for Opioid Use Disorder see CIP Medication Assisted Therapy protocol (optional)
  - e. Intervention resource referrals
- V. Consider transport to the emergency department for the following:
  - a. COWS score >36
  - b. CIWA score greater than or equal to 9
- VI. On-scene education and suggested support sources may include:
  - a. Harm reduction/safer use education
  - b. Syringe Service Program (SSP) opportunities

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



SUBSTANCE USE DISORDER CARE

Initial Date: November 19, 2020

Revised Date: Section 11-63

- c. Risks of self-medicating
- d. Withdrawal risks
- e. Local resources

## COWS Wesson & Ling, J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. Clinical Opiate Withdrawal Scale

Resting Pul		GI Upset: over last 1/2 hour
Measured a	fter patient is sitting or lying for one minute	0 No GI symptoms
0	Pulse rate 80 or below	1 Stomach cramps
1	Pulse rate 81-100	2 Nausea or loose stool
2	Pulse rate 101-120	3 Vomiting or diarrhea
4	Pulse rate greater than 120	5 Multiple episodes of diarrhea or vomiting
Sweating: over past 1/2 hour not accounted for by room temperature or patient		Tremor observation of outstretched hands
activity.		0 No tremor
0	No report of chills or flushing	1 Tremor can be felt, but not observed
1	Subjective report of chills or flushing	2 Slight tremor observable
2	Flushed or observable moistness on face	4 Gross tremor or muscle twitching
3	Beads of sweat on brow or face	100 Section (1860 (1860 (180) (1800 (1800 (1800 (1800 (1800 (1800 (1800 (1800 (180)
4	Sweat streaming off face	
Restlessness	Observation during assessment	Yawning Observation during assessment
0	Able to sit still	0 No yawning
1	Reports difficulty sifting still, but is able to do so	1 Yawning once or twice during assessment
3	Frequent shifting or extraneous movements of legs/arms	2 Yawning three or more times during assessment
5	Unable to sit still for more than a few seconds	4 Yawning several times/minute
Pupil s <b>ize</b>		Anxiety or irritability
0	Pupils pinned or normal size for room light	0 None
1	Pupils possibly larger than normal for room light	1 Patient reports increasing irritability or anxiousness
2	Pupils moderately dilated	2 Patient obviously irritable anxious
5	Pupils so dilated that only the rim of the iris is visible	4 Patient so irritable or anxious that participation in the
,	r upits so unated that only the rim of the his is visible	assessment is difficult
Bone or Join	at aches If patient was having pain previously, only the additional	Gooseflesh skin
component	attributed to opiates withdrawal is scored	0 Skin is smooth
0	Not present	3 Piloerrection of skin can be felt or hairs standing up on
1	Mild diffuse discomfort	arms
2	Patient reports severe diffuse aching of joints/ muscles	5 Prominent piloerrection
4	Patient is rubbing joints or muscles and is unable to sit still because of discomfort	Section and section and section according to the section and section according to the section and section according to the section according to th
Runny nose	or tearing Not accounted for by cold symptoms or allergies	
0	Not present	Total Score
1	Nasal stuffiness or unusually moist eyes	The total score is the sum of all 11 items
2	Nose running or tearing	Initials of person completing Assessment:
4	Nose constantly running or tears streaming down cheeks	

Score: 5-12 mild; 13-24 moderate; 25-36 moderately severe; more than 36 = severe withdrawal

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Page 2 of 3

Protocol Source/References: https://img.grepmed.com/uploads/1565/withdrawal-diagnosis-addiction-opiate-scale-original.jpeg https://www.aafp.org/afp/2013/1101/p589.html



#### **Treatment Protocol** SUBSTANCE USE DISORDER CARE

Initial Date: November 19, 2020

Revised Date:	Section 11-63

Patient:	Date:	Time:	(24-hour clock, midnight = 00:00)
Pulse or heart rate, take	en for one minute: _	Blood pressure:	
NAUSEA AND VOMITING		AUDITORY DISTURBANCES	HEADACHE, FULLNESS IN HEAD
Ask "Do you feel sick to you		Ask "Are you more aware of sounds around	Ask "Does your head feel different? Does it
you vomited?" Observation		you? Are they harsh? Do they frighten you?	feel like there is a band around your head?"
0 No nausea and no vom	g	Are you hearing anything that is disturbing to you? Are you hearing things you know are not	Do not rate for dizziness or lightheadedness. Otherwise, rate severity.
1 Mild nausea with no vo	omiting	there?" Observation.	0 Not present
2		0 Not present	1 Very mild
3		Very mild harshness or ability to frighten	2 Mild
4 Intermittent nausea wit	th dry heaves	2 Mild harshness or ability to frighten	3 Moderate
5		3 Moderate harshness or ability to frighten	4 Moderately severe
6		4 Moderately severe hallucinations	*
7 Constant nausea, frequ	ient dry heaves and	5 Severe hallucinations	5 Severe
vomiting		6 Extremely severe hallucinations	6 Very severe
		7 Continuous hallucinations	7 Extremely severe
TACTILE DISTURBANCES			AGITATION
Ask "Have you had any itchi		PAROXYSMAL SWEATS	Observation.
needles sensations, burning do you feel like bugs are cra		Observation.	
your skin?" Observation.	willing off of direct	No sweat visible	0 Normal activity
0 None		Barely perceptible sweating, palms moist	1 Somewhat more than normal activity
1 Very mild itching, pins	and needles.	2	2
burning or numbness	,	3	3
2 Mild itching, pins and r	needles, burning or	4 Beads of sweat obvious on forehead	4 Moderately fidgety and restless
numbness		5	5
3 Moderate itching, pins	and needles,	6	6
burning or numbness			7 Paces back and forth during most of
4 Moderately severe hall	ucinations	7 Drenching sweats	the interview, or constantly thrashes about
5 Severe hallucinations			about
6 Extremely severe halluc		VISUAL DISTURBANCES	ORIENTATION AND CLOUDING OF
7 Continuous hallucination		Ask "Does the light appear to be too bright? Is its color different? Does it hurt your eyes?	SENSORIUM
TREMOR		Are you seeing anything that is disturbing to you? Are you seeing things you know are not	Ask "What day is this? Where are you? Who am I?"
Arms extended and fingers		there?" Observation.	Oriented and can do serial additions
Observation.	oproduction	0 Not present	Cannot do serial additions or is
1 Not visible, but can be	felt fingertip to	1 Very mild sensitivity	uncertain about date
fingertip	3	2 Mild sensitivity	2 Disoriented with date by no more than
2		3 Moderate sensitivity	two calendar days
3		4 Moderately severe hallucinations	3 Disoriented with date by more than
4 Moderate, with patient	t's arms extended	5 Severe hallucinations	two calendar days
5		6 Extremely severe hallucinations	4 Disoriented with place or person
6		7 Continuous hallucinations	
7 Severe, even with arms	not extended	/ Continuous Handelhations	
		ANXIETY	
		Ask "Do you feel nervous?" Observation.	
		0 No anxiety, at ease	
		1 Mildly anxious	
		2	
		3	
		4 Moderately anxious, or guarded, so anxiety is inferred	
		5	
		6	Total CIWA-Ar score:
		7 Equivalent to acute panic states as seen	Rater's initials:
		in severe delirium or acute schizophrenic reactions	Maximum possible score is 67

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

Page 3 of 3



### Treatment Protocol SKIN RASH COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-75

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with skin rashes, provide initial treatment and differentiate between the patients who will require ED evaluation vs. alternatives such as treatment on scene or alternative destinations.

Aliases: Hives, rash

- I. Apply gloves prior to patient contact
- II. Follow CIP Patient General Assessment and Care protocol
- III. Obtain additional history and vital signs including the following:
  - a. Time of onset, duration of complaint
  - b. History of previous similar complaints and treatment required
  - c. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
  - d. Location, size, and description of affected area
  - e. Extent of skin changes
  - f. Redness, drainage, weeping, ascending redness, warmth of skin, pain
  - g. Presence of pain
  - h. History of exposure oral (food/medications)
  - i. History of exposure skin contact (poison ivy/oak, new products)
  - j. Illness
- IV. Consider transport to the emergency department for the following patients **see**CIP Medical Direction protocol:
  - a. Suspected severe reactions such as Stevens- Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
  - a. Systemic symptoms
  - b. Vital sign changes or instability
  - c. Altered level of consciousness
  - d. Ascending redness
  - e. Presence of fever
- V. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Generalized itchy rash/pruritis
    - i. Diphenhydramine 25-50mg PO/IM/IV
      - 1. Pediatrics: 1 mg/kg up to the adult dose
    - ii. Steroids
      - 1. Methylprednisolone
        - a. Adult 125 mg IV/IO
        - b. Pediatrics 2mg/kg IV/IO (max does 125 mg)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



### Treatment Protocol SKIN RASH COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-75

2. Prednisone

a. Adults and children over 6 years old 50 mg tablet PO

iii. Monitor for changes and systemic symptoms after

c. Localized itchy rash (example: contact dermatitis, urticaria/hives, scabies)

i. Hydrocortisone 1% topical ointment/cream treatment

ii. Topical diphenhydramine

- d. Other rashes
  - i. If suspected zoster virus contact physician
  - ii. If rash involves palms and soles, contact physician for consideration of possible syphilis or hand/foot/mouth disease
  - iii. If suspected scabies contact physician
  - iv. Rashes with changes or systemic symptoms contact physician
- VI. Counsel/Educate
  - a. Minimizing contact with allergen

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol URINARY COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-76

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with a urinary complaint, provide initial treatment and differentiate between the patients who will require ED evaluation vs, alternatives such as treatment on scene or at alternative destinations.

Aliases: Urinary retention, painful urination, blood in urine, urinary tract infection

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtaining additional history and vital signs including the following:
  - a. Time of onset, duration of complaint
  - b. History of previous similar complaints and treatment required
  - c. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
- III. Diagnostics to consider:
  - a. Urinary Analysis urine dip stick (clean catch, straight catheterization, new/current Foley specimen) see CIP Specimen Collection protocol
  - b. Urine Culture and Sensitivity
- IV. Patients with any of the following, consider transport to ED **see CIP Medical Direction protocol:** 
  - a. Systemic symptoms
  - b. Vital sign changes or instability
  - c. Significant lab abnormalities
  - d. Altered level of consciousness
  - e. Signs consistent with sepsis see sepsis protocol
- V. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. If urine is positive for infection, consider oral and/or IV antibiotics
    - i. PO Antibiotics
      - 1. Cephalexin 500 mg. QID 3-10 days
      - 2. Trimethoprim/Sulfamethoxazole 160 mg/800 mg BID 5-10 days
      - 3. Ciprofloxacin 500mg. QID. 3-10 days. Note concern for tendonitis and tendon rupture after treatment
    - ii. IV Antibiotics
      - 1. Per physician's order and supply
  - c. Analge<u>sics</u>
    - i. Phenazopyridine (Pyridium) 95 mg PO

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



URINARY COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-76

ii. Ad

Acetaminophen PO (Max dose 650 mg)

iii.

Ibuprofen PO (Max dose 600 mg)

d. If urine is negative for infection and urinary retention is suspected, consider urethral catheter insertion see Urinary Catheter protocol

VI. Counsel/Educate

- a. Hydration
- b. Pain management
- c. When to contact a health care provider

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



#### GASTROINTESTINAL COMPLAINTS

Initial Date: December 14, 2020

Revised Date: Section 11-77

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with gastrointestinal complaints, provide initial treatment and differentiate between the patients who will require ED evaluation vs, alternatives such as treatment on scene or at alternative destinations.

Aliases: Constipation, upset stomach, nausea, vomiting, diarrhea.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtaining additional history and vital signs including the following:
  - a. Time of onset, duration of complaint
  - b. History of previous similar complaints and treatment required
  - c. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
  - d. Presence of blood in stool or emesis
  - e. Presence of pain
  - f. Orthostatic vitals
- III. Diagnostics to consider
  - a. Urine pregnancy if available
  - b. Electrolytes if available
  - c. Blood Glucose
- IV. Patients with any of the following, consider transport to ED **see Medical Direction protocol:** 
  - a. Systemic symptoms
  - b. Vital sign changes or instability
  - c. Presence of blood in stool or emesis
  - d. Presence of abdominal pain or tenderness
  - e. Altered level of consciousness
  - f. Abnormal lab values
- V. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic.
  - b. Fluid
    - i. IV fluid bolus maximum up to 2 liters for signs of dehydration
      - 1. Caution with CHF and renal patients, consult physician prior to administration
  - c. Nausea/Vomiting
    - Ondansetron (Zofran) 4mg IV/IM
      - 1. Repeat one time if nausea and vomiting still present after 45 minutes

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025




### Treatment Protocol GASTROINTESTINAL COMPLAINTS

Initial Date: December 14, 2020

Revised Date: Section 11-77

d. OR	
-------	--



1. Repeat one time if nausea and vomiting still present after 45 minutes

#### e. Pain

- i. Compazine 10 mg IM or slow IV push
  - 1. Lower dose for patients using other sedative medications
  - 2. Lower dose for elderly patients

3.

- a. Monitor for dystonic reaction or akathisia
- b. Administer diphenhydramine 50 mg IV/IM If symptoms are not resolved within 20 minutes consider transport.
- ii. Acetaminophen 325 mg PO (Max dose 650 mg)
  - Ibuprofen 200 mg PO (Max dose 600 mg)
- VI. Counsel/Educate

iii.

- a. PO recommendations
- b. When to contact a health care provider

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol SUSPECTED RESPIRATORY INFECTION COMPLAINT

Initial Date: December 21, 2020

Revised Date: Section 11-78

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with suspected respiratory infection complaints, provide initial treatment and differentiate between the patients who will require ED evaluation vs, alternatives such as treatment on scene or at alternative destinations.

Aliases: Viral URI, cold, flu.

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtaining additional history and vital signs including the following:
  - a. Time of onset, duration of complaint
  - b. History of previous similar complaints and treatment required
  - c. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
  - d. SpO2
  - e. Specimen and Collection protocol
- III. Patients with any of the following, consider transport to ED see CIP Medical Direction protocol:
  - a. Systemic symptoms
  - b. Vital sign changes or instability
  - c. Presence of blood in sputum
  - d. Presence of pain
  - e. Altered level of consciousness
  - f. Hypoxia on room air
  - g. Presence of fever
- IV. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Fluid
    - i. IV fluid bolus up to a maximum of 2 liters
      - 1. Caution with CHF and renal patients, consult physician prior to administration
  - c. Antibiotics for suspected respiratory infection upon physician's orders.
    - Azithromycin 250 mg tab PO. Two (2) on first day followed by 1 daily for 4 additional days
    - ii. Doxycycline 100 mg tab PO, BID
  - d. Antipyretics/Analgesics
    - . Acetaminophen 325 mg PO (Max dose 650 mg)

MCA Name: Marquette Alger MCA

MCA Board Approval Date: Click here to enter text.

MCA Implementation Date: 1/31/2025



#### SUSPECTED RESPIRATORY INFECTION COMPLAINT

Initial Date: December 21, 2020

Revised Date: Section 11-78

ii. Ibuprofen 200 mg PO (Max dose 600 mg)

V. Counsel/Educate

a. PO recommendations

b. When to contact a health care provider

MCA Name: Marquette Alger MCA

MCA Board Approval Date: Click here to enter text.

MCA Implementation Date: 1/31/2025



#### SORE THROAT COMPLAINTS

Initial Date: December 21, 2020

Revised Date: Section 11-79

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with an isolated sore throat without other respiratory complaints and differentiate between the patients who will require ED evaluation vs, alternatives such as treatment on scene or at alternative destinations.

Aliases: Sore throat, strep throat, croup

- I. Follow CIP Patient General Assessment and Care protocol
- II. Obtain additional history and assessment including the following:
  - a. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
  - b. Detailed examination of the face, neck, mouth
- III. Diagnostics to consider
  - a. Strep test or other throat cultures per physician order see Specimen and Collection protocol
  - b. Lab draw for blood tests (example: mono spot) per physician's order **see Specimen and Collection protocol**
- IV. Patients with any of the following, consider transport to ED **see CIP Medical Direction protocol:** 
  - a. Systemic symptoms
  - b. Vital sign changes or instability
  - c. Significant lab abnormalities
  - d. Altered level of consciousness
  - e. Facial or neck swelling
  - f. High fever
  - g. Significant voice change "hot potato voice"
  - h. Uvula deviation or swelling
  - i. PO Intolerance
  - j. Inability to swallow/drooling
  - k. Fatigue
  - I. Loss of appetite
  - m. Body aches
  - n. Chills
  - o. Stridor
- V. On-scene medication administration may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. Fluid



MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



### Treatment Protocol SORE THROAT COMPLAINTS

Initial Date: December 21, 2020

Revised Date: Section 11-79

1. Caution with CHF and renal patients, consult physician prior to administration c. Antipyretics/Analgesics i. Acetaminophen 325 mg PO (Max dose 650 mg) (optional) ii. Ibuprofen 200 mg PO (Max dose 600 mg) Throat lozenges d. Antibiotics for suspected strep upon physician's orders. i. Strep 1. Penicillin V potassium 500 mg PO, QID. 7-10 days 2. Amoxicillin 500 mg PO, TID 7-10 days. 3. Cephalexin 500 mg PO, QID. 7-10 days Azithromycin 250 mg PO, Two (2) tablets on the first day 4. followed by 1 daily for 4 additional days

Amoxicillin/clavulanate 500 mg/125 mg PO

- VI. Counsel/Educate
  - a. PO recommendations

5.

b. When to contact a health care provider

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025 Protocol Source/References:



### Treatment Protocol NOSEBLEED COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-80

This protocol is for trained CIP Paramedics only. If during assessment, procedure, or treatment the patient is found to have a medical emergency in need of hospital treatment, the CIP visit will be suspended, and local MCA protocols utilized.

**Purpose:** To provide guidelines for CIP paramedics to assess a patient with a nosebleed, provide initial treatment and differentiate between the patients who will require ED evaluation vs, alternatives such as treatment on scene or at alternative destinations.

- I. Follow CIP Patient General Assessment and Care protocol
- II. On scene treatment for patients who are actively bleeding upon initial evaluation
  - a. Have patient blow nose to remove clots
  - b. Provide direct pressure to the nose for 10-15 minutes while preventing swallowing of blood as this may irritate the stomach
  - c. CAUTION if posterior source suspected at any time during treatment initiate 9-1-1 for immediate transport and begin/continue treatment
- III. Obtaining additional history including the following:
  - a. Time of onset of current nosebleed
  - b. Mechanism or cause of nosebleed (use of oxygen without humidification, digital trauma, foreign body, spontaneous)
  - c. History of previous nosebleeds and treatment required
  - d. Use of medication which may affect treatment of nosebleed such as Aspirin or systemic anticoagulants (Lovenox, Coumadin, other novel oral anticoagulants, etc.).
  - e. Presence of systemic symptoms: fever, chills, diaphoresis, weakness, dizziness, changes in mental status, breathing difficulty, chest pain, etc.).
- IV. Diagnostics to consider
  - a. Hgb
  - b. PT/INR.
- V. Patients with any of the following, consider transport to ED **see CIP Medical Direction protocol:** 
  - a. Significant trauma
  - B. Continued bleeding despite treatment (consider possibility of posterior nosebleed) Systemic symptoms
  - c. Vital sign changes or instability
  - d. Significant lab abnormalities
  - e. Altered level of consciousness
- VI. On-scene medication administration and treatment may include:
  - a. Use of approved MCA protocols and medications up to the extent of standard paramedic treatment according to protocol.
  - b. If still actively bleeding provide direct pressure for an additional 10-15 minutes.
    - i. Consider the administration of the following:
      - 1. Oxymetazoline (Afrin) 2-3 sprays in the affected nostril (medication is single patient use)

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



### Treatment Protocol NOSEBLEED COMPLAINT

Initial Date: December 14, 2020

Revised Date: Section 11-80

- a. Do not use in patients less than 6 years old
- b. Do not leave oxymetazoline (Afrin) with patient
- ii. If bleeding is still active see CIP Medical Direction protocol
- iii. Consider nasal packing see CIP Nasal Packing and Nasal Packing Removal protocol
- c. Once bleeding has stopped consider the following for prevention of rebleeding
  - i. **D**bacitracin
    - 1. Apply just inside the infected nostril
  - ii. aline ointment
  - iii. Saline nasal spray if available
- VII. Counsel/Educate
  - a. Self-treatment options
  - b. Prevention

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



SEXUAL ASSAULT FOLLOW UP

Initial Date: 10/28/2022

Revised Date: Section 11-81

#### Sexual Assault Follow Up (Optional)

#### I. Indications

- A. Patients who have had a sexual assault, do not have acute injury, and have been referred for follow-up.
- B. Patients who have experienced a sexual assault and refuse transportation to the hospital or other follow-up resources but consented to CP follow-up.

\*NOTE: Providing a follow up care does not preclude other treatment protocols nor the need for transportation to an emergency department. Oxygenation, ventilation, and treatment of injury are the primary goals of treatment. Transport to a specialty facility or follow up with specialty care is preferred.

#### II. Procedure

- A. Assess patient and treat according to Patient Assessment and other indicated protocols (if any).
- B. Be sensitive to the patient's emotional state. Protecting the patient's privacy and respecting the patient's beliefs regarding emergency contraception must be prioritized.
- C. Medications should be offered to appropriate patients who do not have other contraindications. The offer must include an objective explanation of the benefits and risks of use, as outlined in the medications being provided.
- D. For patients at risk of sexually transmitted infections, regardless of timeframe:
  - a. Administer ceftriaxone 500 mg IM
  - b. Administer doxycycline 100 mg AND facilitate prescription for 100 mg
     BID for 7 days
  - c. For male patients, administer metronidazole 2 g PO
  - d. For female patients:
    - i. Administer metronidazole 500 mg PO AND
    - ii. Facilitate prescription for 500 mg PO BID for 7 days
  - e. Access patient's vaccination status of HPV and Hepatitis B. If patient is not vaccinated, refer patient for vaccination.

MCA Name: Marquette Alger MCA
MCA Board Approval Date: 11/12/2024
MCA Implementation Date: 1/31/2025


Page 1 of 3



SEXUAL ASSAULT FOLLOW UP

Initial Date: 10/28/2022
Revised Date: Section 11-81

- E. For patients whose assault was within 72 hours:
  - a. Evaluate for HIV risk



- b. Advise patient of benefit of timely Post Exposure Prophylaxis (PEP) and follow up for 28-day prescription, along with referral to infectious disease clinic, if available.
- F. For patients at risk of pregnancy, within 3 days (72 hours) of assault
  - a. If the CP has a religious objection to emergency contraception, offer information on emergency contraception. If the patient requests access to emergency contraception, facilitate access to emergency contraception.
  - Otherwise, offer emergency contraception, including risks and complications
    - i. Provide fact sheet to patient
    - ii. If patient consents, administer levonorgestrel 1.5 mg PO

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025



SEXUAL ASSAULT FOLLOW UP

Initial Date: 10/28/2022 Revised Date:

Section 11-81

- iii. Advise patient that efficacy is greatly reduced if there is vomiting within 2 hours of taking medicine, and they should follow up with a physician if this happens
- G. Document in Patient Care Record the education provided, medications administered, the patient's if any declination occurs, and referrals or specific resources offered to the patient.
- H. Reiterate to the patient the need for follow-up care and remind of available resources, including:
  - a. Sexual Assault Nurse Examiner or Sexual Assault Response Teams
  - b. Any available literature for local resources

MCA Name: Marquette Alger MCA MCA Board Approval Date: 11/12/2024 MCA Implementation Date: 1/31/2025

A Board Approval Date: 11/12/2024

Protocol Source/References: https://www.cdc.gov/std/treatment-guidelines/sexual-assault.htm